



ASX and Media Release

## **Ex CSL VP Peter Turvey appointed to Viralytics' board**

*CEO Malcolm McColl also appointed as Managing Director & CEO*

**8 September 2014, Sydney, Australia:** Viralytics Limited (ASX:VLA, OTC:VRACY) has appointed former CSL executive Peter Turvey to its board of directors along with CEO Dr Malcolm McColl.

Mr Turvey has been appointed non-executive director. He has over 30 years' experience in the biotechnology sector, 20 of which were spent at CSL Ltd in roles including group general counsel and executive vice president licensing. He is a principal of science and technology advisory services firm Foursight Associates Pty Ltd and is a non-executive director of Ausbiotech Ltd, Starpharma Holdings Ltd, Admedus Ltd and Agriculture Victoria Services Pty Ltd.

In his time with CSL, Mr Turvey was integral to the company transforming from a government owned organisation to a multi-billion dollar global biopharmaceutical company being heavily involved in the acquisitions and divestments of businesses over the period. He was also responsible for licensing and the protection of the company's intellectual property as well as corporate risk management.

He also played a key role in the establishment of the Gardasil Vaccine license to Merck & Co. and the licensing of the Iscomatrix® adjuvant platform technology to the world's leading vaccine manufacturers.

Dr McColl's election to the board and elevation to the position of Managing Director & CEO comes after a very successful first 18 months as CEO of Viralytics. Dr McColl spearheaded the company's recent \$27 million capital raising that saw 12 new specialist healthcare institutional investors become shareholders. The company has also continued to report excellent data from its CAVATAK trials.

Paul Hopper, chairman of Viralytics said, "Peter has arguably one of the finest résumés in the Australian biotech scene and Viralytics will greatly benefit from his knowledge and experience."

"Malcolm has achieved outstanding clinical and corporate results since his appointment as CEO last year and his election to the board reflects his importance to the company's future."

These appointments come as Dr Phillip Altman and Mr Peter Molloy step down from the board. Dr Altman and Mr Molloy devoted seven and six years respectively to their board duties, contributing to the substantial progress of Viralytics in that period.

Paul Hopper said, "Phil Altman and Peter Molloy provided outstanding service to shareholders over many years and we wish them well."

For personal use only



"On behalf of shareholders the company thanks Dr Altman and Mr Molloy for their considerable contributions."

**Enquiries:**  
**Paul Hopper**  
**Chairman**  
**+1 858 334 5820**

**Rudi Michelson**  
**Monsoon Communications**  
**03 9620 3333**

**About Viralytics Ltd:**

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. Viralytics' lead investigational product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CVA21 binds to specific 'receptor' proteins highly expressed on multiple cancer types including, but not limited to: melanoma; prostate, lung, breast and bladder cancers; and multiple myeloma. CAVATAK™ acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells. Together this mechanism of action is known as oncolytic immunotherapy. CAVATAK™'s preferential targeting of cancer cells creates the potential for a more tolerable cancer treatment.

The company has completed enrolment in a single arm Phase 2 clinical trial of intratumourally administered CAVATAK™ in the treatment of Late-stage Melanoma (the CALM study), at multiple prestigious cancer clinics in the US. The study is being conducted in patients with late stage (IIIC and IV) malignant melanoma.

In addition, Viralytics has commenced a Phase 1/2 trial of CAVATAK™ delivered systemically (intravenously). This trial, referred to as the STORM (Systemic Treatment Of Resistant Malignancies) study, is enrolling patients with melanoma, prostate, lung or metastatic bladder cancers. The second stage of the STORM trial will include combination treatments with existing chemotherapies in one of the above cancer types. The STORM trial is being conducted at three UK cancer centres.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market.

For personal use only